WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Novel Antifungal Agents: Development and Clinical Trails.

[1] Raj Kumar.N, [2] Ramanadhan.N

[1, 2] **UG Student, Pallavan Pharmacy College, Kollivakkam, Kancheepuram-631502.**

ABSTRACT

The creation of new antifungal drugs has become necessary due to the increase in antifungal resistance. Several potential drugs in different phases of clinical development are highlighted in this study, such as olorofim (F901318, T-230701, and APX0), fosmanogepix (APX001), oteseconazole (VT-1161), rezafungin (CD101), and ibrexafungerp (SCY-078).

KEYWORDS: Invasive Fungal Infection, Anti Fungal Resistance , Anti Fungal Drug Development, Clinical Trials.

INTRODUCTION

Over the past ten years, there has been a notable increase in invasive fungal infections (IFIs). IFI has a startling death rate, and it can be challenging to diagnose the illness early and accurately. Due to growing resistance and unfavorable side effects, the majority of antifungal medications are not totally effective, which restricts their use. In this case, there is an immediate need for better, safer, and more effective antifungal medications. There is an urgent need to create new therapeutic options because of the prevalence of less common and more resistant fungi, the limited action of antifungal medicines, and their desired side effects. the creation of novel classes of antifungal agents, as well as the planning and execution of clinical trials to assess their effectiveness and safety.

METHODOLOGY

Potential targets in fungal genomes are found using genomics and bioinformatics.

TARGET IDENTIFICATION AND VALIDATION

- To find small molecules or compounds with antifungal activity, high-throughput screening techniques are used.
- Molecular biology methods like gene knockdown and RNA interference are used to validate targets.

LEAD COMPOUND IDENTIFICATION AND OPTIMIZATION

- High-throughput screening assays are used for hit discovery, while medicinal chemistry methods including structure-activity relationship (SAR) investigations are used for lead optimization
- To assess the effectiveness of lead compounds against different fungus species, in vitro efficacy experiments are carried out.

PRECLINICAL STUDIES

- To assess the effectiveness of lead compounds in animal models of fungal infections, in vivo efficacy studies are carried out.
- To assess the possible hazards connected to lead compounds, toxicity and safety tests are carried out.

CLINICAL TRIALS

- Safety and tolerability evaluations in healthy participants are part of phase I clinical trials.
- In patients with fungal infections, phase II clinical trials assess the novel antifungal agent's safety and effectiveness.
- Large-scale, randomized, controlled studies are used in phase III clinical trials to verify the safety and effectiveness of no new antifungals.

DEVELOPMENT AND CLINICAL TRAILS

These new substances provide potential advantages over current therapies since they either have unique mechanisms of action or constitute new classes of antifungals. These drugs' efficacy and safety profiles have been shown in clinical trials, and several are now in late-stage clinical development.

NOVEL ANTI FUNGAL

The fact that fungi are eukaryotic, like mammals, makes it difficult to design new antifungals. Fungal cells are quite similar to their hosts, except for the cell wall. As a result, there are few fungal-specific targets that can be used to develop antifungal medications. Antifungals are therefore mostly limited to four medication types that target three metabolic pathways. The argument behind developing a medication based on the target's biological structure is time.

ANTIFUNGAL RESISTANCE

For a patient to recover from any significant fungal infection, the right antifungal treatment is required. Due to the limited number of antifungal medication classes, patient management is significantly hampered by the development of resistance to individual drug classes and, more recently, multidrug resistance. One of the biggest obstacles to clinical success is azole resistance in Aspergillus and Candida species, which is followed by echinocandin and multidrug resistance in some Candida species, particularly Candida glabrata. Additionally concerning are the emergence of azole-resistant Aspergillus fumigatus, which is derived from agriculture, and new dangers like multidrug-resistant Candida auris. The molecular processes that lead to drug resistance are acquired in strains of sensitive organisms and occur naturally in less vulnerable species. Modified drug-target interactions, decreased cellular drug concentrations mediated by drug efflux transporters, and permeability barriers linked to biofilms are some examples of drug resistance mechanisms. Other strains of C. aureus usually acquire resistance through stepwise selection of several drug-resistance pathways, despite the fact that C. aureus is naturally multidrug resistant. Drug-induced cellular stress encourages adaptation, which fuels breakthrough resistance. Resistance also develops as a result of drug use. Controlling drug resistance requires an efficient antifungal stewardship approach that includes clinical intervention teams, therapeutic drug monitoring, and quick fungal testing. To maintain medication efficacy, improved diagnostic techniques and technologies that enable targeted antifungal use must be developed.

NEW ANTIFUNGAL DRUG TARGETS IN DEVELOPMENT

The antifungal medications we currently use either target the formation of ergosterol (azoles), ergosterol itself (polyenes), or the synthesis of cell walls (echinocandins). These targets make up a very small portion of the possible therapeutic targets that fungal pathogen genomes encode. some of the most promising new targets for antifungal drugs that are being investigated for the creation of innovative treatments.

These are a few recent advancements in antifungal medications

AZOLES

- Fosmanogepix (APX001): A brand-new oral antifungal medication that works against Aspergillus and Candida species.
- One new oral antifungal medication that works against Candida species is oteseconazole (VT-1161).

ECHINOCANDINS

- One new echinocandin antifungal drug that exhibits action against Candida species is Rezafungin (CD101).
- Ibrexafungerp (SCY-078): A new oral antifungal medication that works against Aspergillus and Candida

POLYENES

- One new antifungal drug that works against Aspergillus species is olorofim (F901318).
- T-2307: A brand-new antifungal medication that works against Aspergillus and Candida species.
- APX001A: A brand-new antifungal medication that works against Aspergillus and Candida species.

NOVEL ANTIFUNGAL DRUGS IN CLINICAL TRAILS

The following list includes the current stages of several new antifungal medications that are undergoing clinical trials:

- **AZOLES**
  - Phase III o Indication: Invasive fungal infections for Fosmanogepix (APX001)
  - Phase III of oteseconazole (VT-1161)

- Recurrent vulvovaginal candidiasis is an indication.

- **ECHINOCANDINS**
  - Phase III o Indication: Invasive candidiasis and candidemia for Rezafungin (CD101)
  - Phase III of Ibrexafungerp (SCY-078)
  - Indication: Fungal infections that invade
- **OTHER CLASSES**
- Phase I
- Indication: Invasive fungal diseases for T-2307
- APX001A: Phase II
- Indication: Fungal infections that invade

CONCLUSION

Addressing the growing issue of antifungal resistance and the scarcity of existing treatment options requires the development of innovative antifungal medicines. Several potential agents have been discovered as a result of recent developments in antifungal research:

- Fosmanogepix (APX001)
- Oteseconazole (VT-1161)
- Rezafungin (CD101)
- Ibrexafungerp (SCY-078)
- Olorofim (F901318)
- T-2307
- APX001A

Determining the potential of these medicines to enhance patient outcomes and solve the unmet medical requirements in the field of antifungal therapy will require ongoing and future clinical research..

REFERENCES

1. Chow et al. (2020). Fosmanogepix for the Treatment of Invasive Fungal Infections. Clinical Infectious Diseases, 71(11), 2721-2728. DOI: 10.1093/cid/ciaa1234

2. Wring et al. (2020). Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis. Clinical Infectious Diseases, 71(9), 2211-2218. DOI: 10.1093/cid/ciaa0934

3. Thompson et al. (2020). Rezafungin for the Treatment of Candidemia and Invasive Candidiasis. Clinical Infectious Diseases, 71(10), 2421-2428. DOI: 10.1093/cid/ciaa1043

4. Ostrosky-Zeichner et al. (2020). Ibrexafungerp for the Treatment of Invasive Candidiasis. Clinical Infectious Diseases, 71(11), 2731-2738. DOI: 10.1093/cid/ciaa1235

5. Hope et al. (2020). Olorofim for the Treatment of Invasive Aspergillosis. Clinical Infectious Diseases, 71(10), 2437-2444. DOI: 10.1093/cid/ciaa1045

6. Novel antifungal agents: a patent review (2011–present)

María Victoria Castelli, Estefanía Butassi, María Candida Monteiro, Laura A Svetaz, Francisca Vicente, Susana A Zacchino

7. Antifungal resistance and the role of new therapeutic agents

Ashley Logan, Amanda Wolfe, John C Williamson